Basal cell carcinoma is the most common form of skin cancer and usually found on the upper body. As this cancer advances it can become disfiguring and fatal.
After a few years of testing and clinical trials the FDA has approved a new drug called Erivedge.
Testing found that the drug, Erivedge, shrank tumors in 30 percent of patients whose disease had metastasized and spread in the body. Also, 43 percent of patients in which the disease had spread to surrounding tissue had a complete or partial response.
Erivedge, a pill taken once a day, works by blocking the signals in the cellular pathway that leads to cancer growth.
Scottsdale Healthcare and TGen began working on Phase 1 of the drug's clinical trial in 2007, through a partnership the entities have maintained for seven years.
It is amazing how those in cancer research are committed to improving the lives of cancer patients!
Genetic testing for predisposition to certain cancers has really advanced in the past few years. The most popular genetic testing is for breast cancer called BRAC testing. Now the cancer that targets men which is prostate cancer can result of a gene mutation. Some men with prostate cancer have a strong hereditary predisposition due to the gene mutation.
Men with prostate cancer were 20.1 times more likely than controls (P=8.5×10−7) to carry a mutation in HOXB13, which plays a key role in prostate development, Kathleen A. Cooney, MD, of the University of Michigan in Ann Arbor, and colleagues found.
The HOXB13 G84E mutation was significantly more common in early-onset, familial prostate cancer than in cases that developed later in life in men without a strong family history of the disease (3.1% versus 0.6%, P=0.000002).
The mutation won't explain many prostate cancer cases but is a good start, the group noted in the Jan. 12 issue of the New England Journal of Medicine.
"Although the variant accounts for a small fraction of all prostate cancers, this finding has implications for prostate-cancer risk assessment and may provide new mechanistic insights into this common cancer," they wrote.
Men whose family has a history of prostate cancer can now be tested for the gene mutation. When the kit becomes available one need to see the cost and if insurance will pay for the testing.
The Pathwork Tissue of Origin Test is the only FDA-cleared, Medicare-covered molecular diagnostic for identifying tissue of origin. It uses a tumor’s own genomic information to help pathologists and oncologists diagnose challenging cancer cases such as those that are metastatic or that have a complex clinical history.
“The Tissue of Origin Test significantly altered clinical practice patterns for treating metastatic cancer,” explained John Hornberger, M.D., M.S., CEO/President of Cedar Associates LLC and Principal Investigator of the study. “We saw an increase in overall survival and quality-adjusted life years, resulting in an expected cost per QALY of less than $50,000 per patient, which is within the generally accepted threshold of <$100,000 for cost-effectiveness in the United States.”1,2
The Pathwork Tissue of Origin Test, available through the Pathwork Diagnostics Laboratory, measures gene expression levels of 2,000 genes and uses proprietary algorithms to compare the tumor’s gene expression pattern to that of 15 tumor types, representing 58 morphologies and 90% of all solid tumors. The test provides objective genomic information to help the physician diagnose what type of cancer the patient has. An accurate diagnosis allows oncologists to match therapy to the cancer.
The Pathwork Tissue of Origin Test has been extensively evaluated in multiple independent studies involving more than 1,100 patient specimens, including large validation studies published in the Journal of Clinical Oncology and the Journal of Molecular Diagnostics.
A retrospective study of 111 cases from 66 academic and community oncology practices illustrates the use of the test in management of cancer patients. Over two thirds of the cases reviewed showed cancer management changed after the Pathwork Tissue of Origin Test result was received. The majority of the oncologists identified the Tissue of Origin Test results as influencing the decision to make a change in therapy.
For more information: http://www.genengnews.com/industry-updates/pathwork-tissue-of-origin-test-cost-effective-for-increasing-cancer-patient-survival/139175622/
Squamous Cell Carcinoma is the second most common skin cancer. This cancers results from the uncontrolled rapid growth of abnormal cells.
The main symptom is a growing bump that may have a rough, scaly surface and flat reddish patches.
Squamous Cell Carcinoma under the nail
Below is a slide of a histology slide after biopsy of squamous cell carcinoma.
Squamous Cell Carcinoma is caused by UV rays over a period of a lifetime. Although SCC is usually found on the skin that has been exposed to the sun SCC can also be found in the mucus membranes and genitals.
Skin biopsies are done using a local anesthetic (numbing medicine), which is injected into the area with a small needle. You will likely feel a small pinch and a little stinging as the medicine is injected, but you should not feel any pain during the biopsy. Any biopsy is likely to leave a scar. Since different methods produce different types of scars, you should ask your dermatologist about biopsies and scarring before the procedure is done.
Diagnosis begins with a biopsy of the suspicious growth on skin. This procedure needs to be performed by a dermatologist. Shave biopsy uses a thin surgical blade to shave off the top layers of skin. This is the most common method for diagnosing squamous cell skin cancer. Punch biopsy uses a round, cookie cutter-like tool. It is used to take a deeper skin sample.
Skin biopsies are done using a local anesthetic (numbing medicine), which is injected into the area with a small needle. You will likely feel a small pinch and a little stinging as the medicine is injected, but you should not feel any pain during the biopsy. Any biopsy is likely to leave a scar. Since different methods produce different types of scars, you should ask your dematologist about biopsies and scarring before the procedure is done.
Above is a video of the histology of a squamous cell carcinoma by Washington Deceit. This explains how pathologists view cancerous tissue under the microscope to properly diagnosis the cancer for the doctor.
Below is a video of the treatment options of SCC by Dr. Shane Chapman
This is an educational video that shows what skin looks like and other irregularities concerning the shape of the tumor. You will have understanding as to what the pathologist views under the scope to determine a person's diagnosis of melanoma.
Histology is extremely important in the diagnosis of all cancers. Tissues from biopsies procedures from any part of the body are processed in the histology department. After the tissues are processed the pathologist will view the prepared tissue on slides to determine if cancer is present.
Peter Kilner demonstrates a whole new way of approaching tissue processing with the Thermo Scientific Securesette cassette making it easier and more efficient to carry out biopsies and other tests in the histology lab. http://www.thermoscientific.com/pathology
John Chabot, MD, chief, division of GI/Endocrine Surgery, executive director, Pancreas Center at New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, discusses the current chemotherapy options available to treat pancreatic cancer. The main drug available is gemcitabine
and is currently used in combination therapies.
There are currently trials underway that are demonstrating improved survival with aggressive chemotherapy. Nongemcitabine regiment was identified that proved to be a better treatment option for stage IV pancreatic cancer than gemcitabine. Chabot expects that drugs that are used in other types of cancer will show the most significant improvement in the future.
Researchers from the University of Georgia have developed a vaccine that has shown promising results against cancer, the UGA News Service is reporting.
The vaccine dramatically reduced the size of tumors in laboratory mice and was particularly successful against breast and pancreatic tumors, two of the deadliest forms of cancer, the researchers reported.
"This vaccine elicits a very strong immune response," UGA researcher Geert-Jan Boons wrote. "It activates all three components of the immune system to reduce tumor size by an average of 80 percent."
The vaccine trains the immune system to distinguish and attack cancer cells based on their different chemical structures, said Sandra Gendler, a researcher at the Mayo Clinic in Arizona, which was also involved in the research.
"We are beginning to have therapies that can teach our immune system to fight what is uniquely found in cancer cells," Boons said. "When combined with early diagnosis, the hope is that one day cancer will become a manageable disease."
After further testing in the laboratory, clinical testing could begin in 2013, the researchers said.
